Bronchial Thermoplasty: Effect on Neuronal and Chemosensitive Component of the Bronchial Mucosa (BT-ASMN)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01839591 |
Recruitment Status : Unknown
Verified March 2014 by Nicola Facciolongo, Arcispedale Santa Maria Nuova-IRCCS.
Recruitment status was: Recruiting
First Posted : April 25, 2013
Last Update Posted : April 1, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
In severe bronchial asthma the mechanism of inflammation and bronchospasm is complex and still not clarified. The smooth muscle cells play an important role from the mechanical point of view, as a culmination of neurogenic stimuli and inflammatory cytokines that determine as final effect the bronchospasm and over time a hypertrophy of the muscular coat. There are some other hypothesis that the smooth muscle cells may play a role as central regulator of chemical mediators that cause bronchospasm and inflammation, although there are currently no firm conclusions 2 According to other studies3,the nerve receptors TRANSIENT RECEPTOR POTENTIAL VANILLOID TYPE 1 have a great importance in the complex mechanism of airway inflammation too. (There are at least 4)
These receptors would intervene according to the following mechanism:
- Irritants on the bronchial mucosa stimulate the TRANSIENT RECEPTOR POTENTIAL VANILLOID TYPE 1 present on afferent endings of sensory fibers, unmyelinated C (chemiosensitive neurons)
- On the same afferent axon acting factors with the activation effect (lowering the activation threshold, increase the expression, promote the translocation of TRPV1 receptor on the membrane). Among these factors the neurotrophins of which the most important NERVE GROWTH FACTOR (NGF)
-
The activation of TRPV1 (through release of Ca2 + +) determines two efferent responses:
- CENTRALLY-MEDIATED
- LOCAL AXON Reflex
Investigators hypothesized that BT may have a strong influence on the destruction of nerve receptors TRPV1 and unmyelinated nerve fibers located in the mucosa going to stop reflections both central and local authorities responsible for the activation of bronchospasm. In support of this hypothesis, there are some anatomical studies4, which show that these receptors are more numerous at the level of main bronchi which are the main target of BT. Please note in this context that it is already known that in thermoablations commonly used in cardiology it is used a radio frequency with development of heat controlled to 65 °, as in the BT, able to interrupt the circuit nervous responsible for the activation of the circuit causing the abnormal 'arrhythmia.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Severe Persistent Asthma | Device: catheter ALAIR | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 12 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Basic Science |
Official Title: | Treatment of Bronchial Severe Asthma With Bronchial Thermoplasty. Assessment of Efficacy and Safety of Treatment, Study of Effects on Neuronal and Chemosensitive Component of the Bronchial Mucosa Pre and Post Treatment |
Study Start Date : | March 2013 |
Estimated Primary Completion Date : | April 2015 |
Estimated Study Completion Date : | December 2015 |
Arm | Intervention/treatment |
---|---|
Experimental: Bronchial Thermoplasty
bronchoscopy bronchial thermoplasty catheter ALAIR Boston SCientific asthma
|
Device: catheter ALAIR
Catheter ALAIR Radiofrequency 65°
Other Names:
|
- analysis of the risk and benefit profile with questionnaire ACT and AQLQ [ Time Frame: Change from Baseline in ACT and AQLQ Questionaire one year after the end of the procedure ]
Evaluation of symptom control through the questionnaire ACT (ASTHMA CONTROL TEST) and AQLQ (Asthma quality life Questionaire) according to GINA criteria.
The questionnaires AQLQ and ACT will be collected 3 months before the TB, the day before the procedure, and 3, 6, 12 months after the end of the procedure.
- Analyze the changes in the state of innervation and nerve receptors before and after BT on histological samples of the bronchial mucosa [ Time Frame: biopsies every 4 weeks( during the treatment) ]first biopsies in left lower lobe non yet treated; second biopsies in right lower lobe already treated; third biopsies in upper lobe already treated;
- Evaluate the effect of BT on the run neurogenic inflammation by analysis of the chemical mediators of inflammation on histological samples of the bronchial mucosa. [ Time Frame: biopsies every 4 weeks (during the treatment) ]first biopsies in left lower lobe non yet treated; second biopsies in right lower lobe already treated; third biopsies in upper lobe already treated;

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patient with severe persistent asthma uncontrolled found in stable for at least 3 weeks
- Patient receiving regular treatment with inhaled corticosteroids (beclomethason> 1000 mcg or equivalent) and LABA (salmeterol> = 100 mcg or equivalent)
- AQLQ score <6.25
- FEV1> = 60% predicted
- Patients not smoking for at least one year
Exclusion Criteria:
- acute asthma with life threatening
- concomitant respiratory diseases (eg, COPD or emphysema)
- use of ß-blocker drugs
- severe active infection in the last 2 weeks
- Pacemaker, internal defibrillator or other implanted electronic device.
- Known sensitivity to medications used to perform bronchoscopy, including lidocaine, atropine and benzodiazepines.
- Currently known bleeding disorder is not well controlled.
- Inability to stop prior to the procedure taking anticoagulants, antiplatelet agents, aspirin or non-steroidal anti-inflammatory drugs
- 18 years
- Pregnant women

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01839591
Contact: Nicola Facciolongo NF Facciolongo, M D | 0522-295956 ext +39 | nicola.facciolongo@asmn.re.it | |
Contact: Carla CG Galeone, phD | carla.galeone@asmn.re.it |
Italy | |
REGGIO EMILIA IRCCS, Santa Maria Nuova Hospital | Recruiting |
Reggio Emilia, Italy, 42024 | |
Contact: Nicola NF Facciolongo, MD 0522-295956 ext +39 nicola.facciolongo@asmn.re.it | |
Principal Investigator: Nicola NF Facciolongo, MD | |
Sub-Investigator: Roberto RP Piro, MD | |
Sub-Investigator: Gianluigi GB Bajocchi, MD | |
Sub-Investigator: Francesco FM Menzella, MD | |
Sub-Investigator: Claudia CC Castagnetti, MD | |
Sub-Investigator: Alberto AC Cavazza, MD | |
Sub-Investigator: Vladimiro VP Pietrini, MD | |
Sub-Investigator: Luisa LS Savoldi, Statistics | |
Sub-Investigator: Carla CG Galeone, Biologist |
Principal Investigator: | Nicola NF Facciolongo, M.D. |
Responsible Party: | Nicola Facciolongo, medical doctor, Arcispedale Santa Maria Nuova-IRCCS |
ClinicalTrials.gov Identifier: | NCT01839591 |
Other Study ID Numbers: |
BT-01-ASMN |
First Posted: | April 25, 2013 Key Record Dates |
Last Update Posted: | April 1, 2014 |
Last Verified: | March 2014 |
Asthma Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases |
Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases |